European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 324-332 , March 2008

Pancreatic neuroendocrine tumours

,Accepted 20 July 2007.

References 

  1. Moldow RE, Connolly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677–686
  2. Danforth DN, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery. 1984;96:1027–1037
  3. Heitz PU, Kasper M, Polak JM, Kloppel G. Pancreatic endocrine tumours: immunocytochemical analysis of 125 tumors. Hum Pathol. 1982;13:263–271
  4. Nicholls AG. Simple adenoma of the pancreas arising from an island of langerhans. J Med Res. 1902;8:385
  5. Larsson L. Endocrine pancreatic tumours. Hum Pathol. 1978;9:401
  6. Chen H, Hardacre JM, Uzar A, Cameron JL, Chot MA. Isolated liver metastases from neuroendocrine tumors: does surgical resection prolong survival?. J Am Coll Surg. 1998;187:88
  7. Kloppel G, Heitz PU. Pancreatic endocrine tumours. Pathol Res Pract. 1988;183:155
  8. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv. 1995;425:547
  9. Thompson NW, Eckhauser FE. Malignant islet cell tumors of the pancreas. World J Surg. 1984;8:940–951
  10. Thompson GB, Van Heerden JA, Grant CS, Carney A, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty year experience. Surgery. 1988;104:1011–1017
  11. Grant CS. Surgical management of malignant islet cell tumours. World J Surg. 1993;17:498–503
  12. Weber HC, Venzon DJ, Lin JT. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1673–1649
  13. Yu F, Vernon DJ, Serrano J. Prospective study of the clinical course, prognostic factors and survival in patients with Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615–630
  14. Hochwald SN, Lee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–2642
  15. Phan GQ, Yeo CJ, Ruben RH. Surgical experience with pancreatic and per pancreatic neuroendocrine tumours: review of 125 patients. J Gastrointest Surg. 1998;2:473–482
  16. Roy P, Venzon DJ, Shojamanesh H. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine. 2000;79:379–411
  17. Gorman B, Charboneau JW, James EM, Reading CC, Galiber AK, Grant CS. Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR Am J Roentgenol. 2003;181:987–992
  18. Galiber AK, Reading CC, Charboneau JW, Sheedy PF, James EM, Gorman B. Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. Radiology. 1988;166:405–408
  19. Vilmann P, Hancke S, Henriksen FW, Jacobsen GK. Endoscopically-guided fine needle aspiration biopsy of malignant lesions in the upper gastrointestinal tract. Endoscopy. 1993;25:523–527
  20. Anderson MA, Carpenter S, Thompson NW. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumours of the pancreas. Am J Gastroenterol. 2000;95:2271–2277
  21. De Angelis C, Carucci P, Repici A, Rizzetto M. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound. 1999;10:139–150
  22. McLean AM, Fairclough PD. Endoscopic ultrasound in the localization of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:177–193
  23. Zimmer T, Stolzel U, Bader M. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996;39:562–568
  24. Cadiot G, Lebtahi R, Sarda L. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somostatin receptor scintigraphy. Gastroenterology. 1996;111:845–854
  25. Mertz H, Gautam S. The learning curve for EUS-guided FNA of pancreatic cancer. Gastrointest Endosc. 2004;59:33–37
  26. Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987–992
  27. Brizi MG, Natale L, Manfredi R, Sallustico G, Vecchioli A, Marano P. High resolution spiral computed tomography of the pancreas. Rays. 2001;26:111–115
  28. Van Hoe L, Gryspeerdt S, Marchal G, Baert AL, Merters L. Helical CT for the preoperative localization of islet cell tumours the pancreas: value of arterial and parenchymal phase images. Am J Roentgenol. 1995;165:1437
  29. Fidler JL, Johnson CD. Imaging of neuroendocrine tumors of the pancreas. Intl J Gastrointestinal Cancer. 2001;30:73
  30. Smelka RC, Cumming MJ, Shoenut JP, Magro CM, Yaffe CS, Kroeker MA. Islet cell tumours: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology. 1993;186:799–802
  31. Muller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT and MR imaging. Radiology. 1994;190:745–751
  32. Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimer AA, Clark OH. Localization of insulinomas. Arch Surg. 1999;134:818–823
  33. Lo CY, Chan FL, Tam SC, Cheng PW, Fan ST, Lam KS. Value of intraarterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery. 2000;128:903–909
  34. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178:237–241
  35. Aoki T, Sakon M, Ohzato H, Kishimoto S, Oshima S, Yamada T. Evaluation of preoperative and intraoperative arterial stimulation and venous sampling for diagnosis and surgical resection of insulinoma. Surgery. 1999;126:968–973
  36. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269–273
  37. van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioceptor imaging. Endocrine. 2003;20:307–311
  38. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastropancreatic system. Ann Oncol. 2004;15:966–973
  39. Knenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin receptor scintigraphy in gastropancreatic tumors: an overview of European results. Ann N Y Acad Sci. 1994;733:416
  40. Scherubl H, Boder M, Fett U, et al. Somatostatin receptor imaging of neuroendocrine gastropancreatic tumors (comment). Gastroenterology. 1993;105:1705
  41. Grover AC, Skarulis M, Alexander R, et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery. 2005;138:1003–1008
  42. Glaser KS, Tschmelitsch J, Klinger A, Klinger P, Bodner P. “Is there a role for laparoscopic ultrasonography (LUS)?”. Surg Laparosc Endosc. 1995;5:370–375
  43. Rosiere A. Neuroendocrine tumors of the pancreas- benefits of new technologies. Surg Endosc. 2005;19:1004–1005
  44. Marks V, Teale JD. Hypoglycemia: factitous and felonious. Endocrinol Met Clin North Am. 1999;28:579–601
  45. Scarlett JA, Mako ME, Rubenstein AH, Blix PM, Goldman J, Horwitz DL. Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin binding antibodies. N Engl J Med. 1977;297:1029–1032
  46. Grant CS. Insulinoma. Surg Oncol Clin North Am. 1998;7:819–844
  47. Buttger TC, Junginger T. Is preoperative radiographic localization of islet cell tumours in patients with insulinoma necessary?. World J Surg. 1993;17:427
  48. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4):1–16iv
  49. Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicentre European study of 127 patients. Surgery. 2005;137:597–605
  50. Danforth DN, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery. 1988;104:1027–1037
  51. Thompson GB, van Heerden JA, Grant CS, Carney JA, Iistrup DM. Islet cell carcinomas of the pancreas: a twenty year experience. Surgery. 1988;96:1011–1017
  52. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999;10(Suppl):6
  53. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine. 2000;79:379
  54. Howard TJ, Stabile BE, Zinner MJ, Chang S, Bhagavan BS, Passaro E. Anatomic distribution of pancreatic endocrine tumors. Am J Surg. 1990;159:258
  55. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. (comment). Ann Intl Med. 1993;119:199
  56. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in Patients with Gastrinoma. Ann Surg. 2006;244:410–419
  57. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8–18
  58. Norton JA. Gastrinoma: advances in localization and treatment. Surg Oncol Clin North Am. 1998;7:845–8610
  59. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison Syndrome. N Engl J Med. 1999;341:635–644
  60. Becker SW, Khan D, Rothman S. Cutaneous manifestations of internal malignant tumours. Arch Dermatol Syphilol. 1942;45:1069–1080
  61. Werners RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63
  62. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis and treatment. Endocr Rev. 1981;2:347
  63. Nightingale KJ, Davies MG, Kingsworth AN. Glucagonoma syndrome: survival 24years following diagnosis. Digest Surg. 1999;16:68–71
  64. Altimari AF, Bhoopalam N, O'Dorsio T, Lange CL, Sandberg L, Prinz RA. Use of a somatostatin analogue (SMS 201–995) in the glucagonoma syndrome. Surgery. 1986;100:989–996
  65. Priest WM, Alexander MK. Islet-cell tumour of the pancreas with peptic ulceration, diarrhea, and hypokalaemia. Lancet. 1957;2:1145
  66. Verner JV, Morrison AB. Islet-cell tumour and a syndrome of refractory watery diarrhea and hypokalaemia. Am J Med. 1958;25:374
  67. Maton PN, O'Drisio TM, Howe BA, et al. Effect of long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. N Engl J Med. 1985;17:312
  68. Kazanijian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumours. Results of 70 cases. Arch Surg. 2006;141:765–770
  69. Norton JA. Somatostatinoma and rare pancreatic endocrine tumours. In:  Clarke OH,  Duh QY editor. Textbook of endocrine surgery. Philadelphia: WB Saunders; 1997;p. 626
  70. Mozell E, Stenzel P, Woltering EA, Rosch J, O'Doriso TM. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr Prob Surg. 1990;27:303–386
  71. Perry RR, Vinik A. Clinical review 72. Diagnosis and management of functioning islet cell tumours. J Clin Endocrinol Metab. 1995;80:2273–2278
  72. Gribril F, Doppman JL, Jensen RT. Recent advances in the treatment of metastatic pancreatic neuroendocrine tumours. Semin Gastrointestin Dis. 1995;6:114–121
  73. Arnold R, Trautmann ME, Creutzfedt W. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–480
  74. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumours. Variables affecting response rates and survival. Cancer. 2005;104:1590–1602

PII: S0748-7983(07)00522-7

doi: 10.1016/j.ejso.2007.07.209

European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 324-332 , March 2008

Article Tools

* Image Usage & Resolution